{"disease":{"id":"radioactive-iodine-refractory-differentiated-thyroid-cancer","name":"radioactive iodine refractory differentiated thyroid cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06970353","title":"Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04560127","title":"Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}